Background. Cytomegalovirus (CMV) infection causes morbidity in solid organ transplant (SOT) recipients, either by direct injury or in association with chronic allograft rejection or other opportunistic infections. Ganciclovir is the treatment of choice, but this agent requires intravenous administration, which affects its feasibility for longterm use. Valganciclovir, which has an oral bioavailability of 60%, has proven to be useful for prophylaxis of CMV infection in high-risk SOT recipients and for treating retinitis in persons with acquired immunodeficiency syndrome.
therapy, in which prophylaxis is targeted toward a subset of patients with early viral replication detected by antigenemia or CMV DNA analysis [2] ; and (2) prophylaxis, in which the drug is administered to all patients, usually for 90-100 days after transplantation [3] . Under some circumstances, prophylactic treatment is considered a risk factor for the development of antiviral drug resistance [4] . Preemptive therapy is of short duration and is specifically directed toward patients who have been identified as having a high risk for CMV disease, thus sparing many persons from the toxicity related to long-term use of antiviral prophylaxis. Monitoring is essential for these patients, and antiviral therapy is initiated at the time when relevant CMV activity is detected. The efficacy of preemptive therapy is supported by the results of randomized, controlled trials [5] . Both of these strategies attempt to avoid establishment of end-organ CMV disease and its complications.
Ganciclovir is a common agent in first-line therapy for CMV infection. Ganciclovir (given either intravenously or orally) can be used for both preventive and preemptive therapy [5] . However, intravenous ganciclovir, although highly effective, is an inconvenient drug regimen for long-term use, because it requires intravenous catheters and hospital stays or frequent home health visits. Oral ganciclovir is more convenient, but its low relative bioavailability (6%) limits the serum concentrations and overall drug exposure that can be achieved [6] .
This situation has changed with the introduction of valganciclovir, a valyl ester prodrug of ganciclovir with an oral bioavailability of ∼60%, which is 10-fold higher than that of ganciclovir capsules. After ingestion, the greatest part of valganciclovir is rapidly converted to ganciclovir by hydrolysis before reaching the systemic circulation. Valganciclovir provides drug exposure comparable to that of intravenous ganciclovir [7] and has been successfully used for CMV prophylaxis in high-risk transplant recipients [8] and for treating CMV retinitis in AIDS patients [9] . It is plausible that the higher bioavailability of valganciclovir will make it useful for treating symptomatic CMV infection as well. Preliminary studies with a small number of patients have offered promising (but limited) information on the value of this drug in SOT recipients [10] [11] [12] [13] [14] [15] [16] [17] .
The objective of our study was to describe our clinical experience regarding the efficacy and safety of oral valganciclovir in patients with preemptive therapy and treatment of CMV disease after SOT.
PATIENTS AND METHODS
From September 2003 through August 2005, 3476 consecutive SOT recipients were prospectively included in an online database in the Spanish Network for Research on Infection in Transplantation (RESITRA), which includes 16 transplantation centers from throughout the country. The database was designed to prospectively compile information related to several pretransplantation, perioperative, and posttransplantation variables, as well as those related to episodes of rejection and infection. In the case of viral infection due to CMV, the data included the clinical presentation (infection, viral syndrome, and focal or disseminated disease), microbiological data (pp65 CMV antigenemia), treatment data, and, finally, outcome (cured or not cured). The treatment data included type of drug (ganciclovir, valganciclovir, foscarnet, or cidofovir), route of administration (oral or intravenous), dose, duration, and reason for switching from one drug to another (failure, toxicity, or other). Informed consent for participation in the study was obtained from all patients.
CMV infection and disease were defined according to established criteria [18] . Infection was defined as documented CMV viremia in the absence of signs and symptoms; disease was defined as a case of viral syndrome, which required antigenemia test results positive for CMV, a temperature of у38ЊC, with no other attributable source, and at least 1 of the following findings: leukocyte count, р4000 cells/mm 3 ; atypical lymphocyte percentage, у3%; and platelet count, р100,000 platelets/mm 3 . Tissue-invasive disease required histopathologic evidence of CMV infection, except for cases of CNS disease or pneumonia, for which the presence of signs or symptoms of disease (combined with detection of CMV in fluid or tissue samples) sufficed.
The CMV antibody status of donors and recipients was determined by ELISA for anti-CMV IgG. CMV pp65 antigen analysis in PBMCs was used to detect CMV in the blood. Each center performed the test with its own commercially available monoclonal antibodies and standard protocol. The pp65 antigen data were reported as the total number of positive cells per PBMCs examined [19] . 5 2 ϫ 10 In the event of CMV-status mismatch (i.e., a CMV-seropositive donor and a CMV-seronegative recipient), intravenous ganciclovir (5 mg/kg per day) was administered on a prophylactic basis, except for lung transplant recipients, who received intravenous ganciclovir at a dosage of 5 mg/kg every 12 h, even when the recipient's CMV seropositivity was the only condition. These patients were switched as soon as possible to oral therapy with either ganciclovir (3 g per day) or valganciclovir (900 mg per day) for the first 100 days after transplantation. In all cases, doses were adjusted on the basis of renal function [20] .
In patients who did not receive CMV prophylaxis, monitoring for CMV infection consisted of blood testing, which was performed weekly for the first 6 weeks after transplantation and every second week thereafter for the next 6 weeks. For patients who received antiviral prophylaxis, monitoring was started after cessation of drug administration and continued up to 1 year after transplantation. Laboratory monitoring of CMV antigenemia was also performed at least weekly during therapy. Additional samples were tested when clinically indicated.
Valganciclovir was given at standard treatment doses (900 mg twice daily, adjusted for renal function), as was intravenous ganciclovir (5 mg/kg twice daily, also adjusted for renal function) [20] . Patients did not receive concurrent Ig treatment. The decision regarding whether a patient was eligible for one treatment or another and its final duration was based on the judgment of the attending physician.
Treatment was considered to be successful if there was resolution of symptoms (when present) and ultimate clearance of antigenemia, without the need for a change in therapy. Treatment failure was defined using the following criteria: (1) the drug was switched to another because of toxicity, failure to decrease CMV pp65 antigen level у1 week after the commencement of treatment onset, poor clinical evolution of focal disease, or any other cause at the discretion of the treating physician; or (2) recurrent viral detection occurred, as determined by pp65 antigenemia, requiring new treatment during the 30 days after completion of the antiviral course. For the purposes of the study, patients who died were not considered to have experienced treatment failure, because, in cases of intrinsically severe disease, the clinical decision would be to treat with intravenous ganciclovir, and this fact could introduce bias in the assessment of this nonrandomized study.
The primary end point of the study was to compare the evolution of CMV infection among the 3 treatment groups. Secondary end points were recurrence of CMV disease and development of adverse effects.
All quantitative variables were expressed as medians with ranges. Between-group differences were calculated with the x 2 test for categorical variables and the Kruskal-Wallis test for quantitative variables. If between-group differences were detected, we used the Mann-Whitney U test with the Bonferroni correction. P values !.05 were considered to indicate statistical significance. Statistical analyses were performed with SPSS software, version 12.0 (SPSS).
RESULTS
A total of 376 episodes of CMV preemptive therapy or disease were recorded among 334 patients. Foscarnet was the initial treatment in 3 episodes, and the treatment was not recorded for another 9 episodes; these 12 episodes were excluded from the analysis. Sixteen patients (15 in the ganciclovir arm and 1 in the ganciclovir-valganciclovir arm) died during the study period. As explained above, these patients were also excluded from the analysis. After these exclusions, patients were divided into 3 groups: (1) ganciclovir recipients, who received intravenous ganciclovir as the primary treatment (155 episodes); (2) valganciclovir recipients, who received valganciclovir as first-line therapy (112 episodes); and (3) ganciclovir-valganciclovir recipients, who received valganciclovir as administered as sequential therapy after intravenous ganciclovir (81 episodes).
Population characteristics are summarized in table 1. The 3 groups were comparable with regard to sex, type of organ transplanted, retransplantation status, CMV donor/recipient status, the fact of having received antiviral prophylaxis, and the day of onset of CMV infection. The pp65 antigen level detected in patients who were treated preemptively was not significantly different among the 3 groups at the time of the diagnosis (median for ganciclovir arm, 20 There were some significant differences between the groups with regard to the median duration of treatment: intravenous ganciclovir preemptive therapy was administered for a shorter duration (15 days) than was ganciclovir-valganciclovir (20 days; ) or valganciclovir alone (21 days; ). For treat-P p .013 P ! .001 ment of viral syndrome, the median duration of therapy with ganciclovir was shorter (18 days) than was the duration for valganciclovir alone (21 days;
). There were no differ-P p .01 ences in the durations for treatment of focal disease (table 2) .
With regard to treatment success, there were no significant differences between the groups for any of the entities studied (i.e., preemptive therapy, viral syndrome, or focal disease). Detailed information is provided in table 2. All patients who experienced treatment failure with ganciclovir (as preemptive therapy for 3 patients, as treatment of viral syndrome for 2, and as treatment of focal disease for 3) had their regimen switched to foscarnet. All patients for whom valganciclovir treatment failed (preemptive therapy for 7 patients, as treatment of viral syndrome for 2, and as treatment of focal disease for 2) had their regimen switched to ganciclovir. All cases resolved with the change of therapy.
There were no significant differences in the recurrence rates among the treatment groups (table 2). Relapse was treated with ganciclovir for 12 episodes, with ganciclovir-valganciclovir for 8 episodes, and with valganciclovir for 5 episodes. Valganciclovir was used as treatment of a relapse episode of a previous valganciclovir treatment in 3 of 7 episodes. All episodes of relapse resolved with re-treatment. Two of the 25 recurrent episodes occurred in patients in whom the first episode was considered to involve treatment failure, and treatment was switched (from ganciclovir to foscarnet in one, and from valganciclovir to ganciclovir in the other).
In valganciclovir recipients, rates of therapeutic success were 84.5% for preemptive therapy, 85% for viral syndrome, and 75% for focal disease. These results were not significantly different from those for patients treated with a sequential scheme (ganciclovir-valganciclovir), for whom the success rates were 90% for preemptive therapy, 96.2% for viral syndrome, and 96.2% for focal disease. In the valganciclovir arm, therapeutic failure (as established on the basis of a change to intravenous ganciclovir) resulted from poor clinical or virologic evolution in 4 episodes (3.6%) and from the attending physician's decision in 7 episodes (6.2%). In another 7 episodes (6.2%), therapeutic failure was attributed to recurrent CMV infection. In the ganciclovir-valganciclovir arm, 4 (4.9%) of 82 episodes involved therapeutic failure, which was attributed to relapse in all cases. Valganciclovir was clinically well tolerated in all patients, and there was no need to withdraw treatment because of toxicity. Detailed information about the valganciclovir arm is provided in table 3.
DISCUSSION
In the current view, prevention of CMV infection after SOT involves preemptive therapy for recognized infection before the onset of overt CMV-associated disease. Detection of markers of early CMV infection is an essential factor for the success of this therapy. Singh [3] reported successful CMV antigenemiadirected prevention through preemptive therapy with oral ganciclovir, compared with intravenous ganciclovir, in 22 liver transplant recipients. Intravenous ganciclovir (5 mg/kg twice per day for 2-3 weeks) remains the current treatment of choice. Early detection of a relevant CMV infection in otherwise asymptomatic patients usually requires hospitalization and specialized care for intravenous drug administration, which is associated with a risk of catheter-related complications, such as bloodstream infections. Therefore, there is an urgent need for an effective oral formulation for preemptive CMV therapy that would enable prevention and treatment of the infection in the outpatient setting, with a significant reduction in health care costs. Valganciclovir circumvents the limitations of oral ganciclovir and offers a true alternative to intravenous ganciclovir for treatment of CMV disease.
In our cohort of 3467 SOT recipients, 334 patients required preemptive therapy or treatment for CMV disease, and more than one-half of the episodes were treated with valganciclovir. Moreover, valganciclovir was mainly prescribed alone (as preemptive therapy) or sequentially (after intravenous ganciclovir for CMV syndrome). The median duration of treatment with valganciclovir was longer than that for ganciclovir for both preemptive therapy and treatment of CMV syndrome. These findings indicate that, for patients without end-organ disease, the advantages of the oral formulation for both first-line therapy and as outpatient treatment after intravenous ganciclovir and hospital discharge outweigh the lack of data on treatment efficacy. Treatment with valganciclovir alone was as successful as treatment with intravenous ganciclovir or sequential treatment with ganciclovir plus valganciclovir as both preemptive therapy and treatment for CMV syndrome (success rate, 84.6% [88 of 104 episodes]). Nevertheless, valganciclovir was used as first-line therapy to treat end-organ disease in only 8 episodes. The success rate was 75% (6 of 8 episodes), however, with no significant differences, compared with the other groups. It should be mentioned that the patients who experienced treatment failure were affected with retinitis and pneumonitis. The remaining 6 patients had gastrointestinal involvement, and valganciclovir was able to resolve the condition.
There are several factors suggesting that oral valganciclovir is as efficacious as intravenous ganciclovir against CMV infection and disease. First, valganciclovir has a favorable pharmacokinetic profile that is essentially similar to that of intravenous ganciclovir, providing similar areas under the curve with the corresponding prophylactic or therapeutic doses, even in liver transplant recipients [7] . Second, oral valganciclovir has proven to be as efficacious as intravenous ganciclovir for treating CMV retinitis in patients with AIDS-arguably a serious challenge for an antiviral agent, considering the profound immunosuppression of these patients and the fact that the eye is a pharmacokinetic compartment where the ganciclovir concentrations required for 50% inhibition of CMV replication are achieved using therapeutic doses [9] . Third, valganciclovir is not only an effective prophylactic drug against CMV in SOT recipients [8] , but it apparently produces high enough levels of ganciclovir to prevent selection of resistant mutations, in contrast to oral ganciclovir [21] . Therefore, valganciclovir offers new therapeutic opportunities by opening the door to preemptive oral therapy and treatment for CMV disease in organ transplant recipients. All of our patients who required preemptive therapy and selected patients with CMV disease were treated on an outpatient basis, an important benefit for their quality of life. The reported data in the literature regarding such patients are very sparse and quite limited but point in the direction of our findings [10] [11] [12] [13] [14] [15] [16] [17] . In various populations, involving a small number of patients and no comparison groups, including renal [10] , cardiac [11, 12] , lung [12, 15] , and liver [17] transplant recipients, valganciclovir seemed to be effective and safe as either preemptive therapy or treatment for viral syndrome. It has been also reported that valganciclovir reduces the CMV DNA level in a manner similar to that of intravenous ganciclovir when given as part of a preemptive strategy [13, 16] . Furthermore, this reduction in the viral load could be useful in deciding the length of treatment, to avoid recurrent infection [22, 23] . In a study that included liver transplant recipients, valganciclovir recipients were compared with a historical cohort of patients who had been given oral ganciclovir as preemptive therapy, and the study demonstrated that valganciclovir was also effective [14] . In contrast to many of the published studies performed with limited samples, the present study of valganciclovir versus intravenous ganciclovir was conducted in a large population that included transplant recipients with high-risk CMV status (i.e., CMV-positive donors and -negative recipients).
There were no significant differences between the treatment groups with respect to the incidence of relapse (valganciclovir arm, 6.2%; ganciclovir-valganciclovir arm, 4.9%; ganciclovir arm, 8.2%). Previous studies have reported higher rates of CMV viremia recurrence; this can be explained by the relatively short course of antiviral treatment administered to some patients and a high percentage of high-risk transplant recipients (CMV-positive donors and -negative recipients) [12, 14] . Our data showed that the proportion of CMV-positive donors and CMV-negative recipients was greater for episodes that experienced relapse (14.3%) than for those that experienced success (9.6%), although the difference was not statistically significant. Again, a previous study of valganciclovir as preemptive therapy reported a recurrence rate similar to ours [10] . In that study, CMV disease occurred mainly in the late posttransplantation period, and many cases were likely to have been late reactivations of infection, which are associated with a lower risk of recurrence [10] .
There was no need to change valganciclovir treatment for any of our patients as a result of adverse events. These data corroborate findings from the literature [10, 11, 13] . Severe drug-related adverse events, such as renal toxicity or neutropenia, have not been observed [11, 13] , and only insignificant adverse effects have been reported [10] .
The main limitations of our study are that facts that it is not a randomized, controlled trial and that there may have been a selection bias related to the patients treated with valganciclovir. Moreover, there were few patients with tissue-invasive disease. Nevertheless, our study demonstrates that oral valganciclovir is a useful therapeutic option for asymptomatic CMV viremia and CMV disease in SOT recipients. Intravenous ganciclovir can be safely replaced by valganciclovir in these patients, thereby leading to a reduction in hospitalization rates and associated costs, both economic and in terms of the patients' quality of life. However, on the basis of rational precautions, patients who are considered for oral therapy should be selected carefully. The course of CMV disease can be severe and rapidly progressive; thus, patients with evidence of malabsorption or with life-threatening CMV disease are likely to be better suited to intravenous ganciclovir treatment. Our data support the findings of previous studies [10] [11] [12] [13] [14] [15] [16] [17] but extend them to include treatment of symptomatic CMV disease in addition to preemptive therapy for CMV disease.
In conclusion, the large majority of patients who require preemptive therapy for CMV disease and selected patients with CMV disease may benefit from treatment with an oral drug that can be used as adequate anti-CMV therapy without the burden of hospitalization. Although our data suggest that valganciclovir therapy can be successful, multicenter, randomized, double-blind clinical trials that focus on preemptive and therapeutic treatment of CMV disease with valganciclovir in SOT recipients are desirable to confirm the results of this observational study.
